Related Experiment Videos
[Polyneuropathy in non-Hodgkin lymphoma]
M Bilińska1, L Usnarska-Zubkiewicz, M Ejma
1Katedry i Kliniki Neurologii AM we Wrocławiu.
Neurologia I Neurochirurgia Polska
|May 1, 1995
Summary
Treatment with oncovin can cause axonal sensorimotor polyneuropathy in 15% of non-Hodgkin lymphoma patients. This nerve damage is linked to treatment, not the specific cancer type, highlighting therapy as a key risk factor.
Area of Science:
- Neurology
- Oncology
Context:
- Non-Hodgkin lymphoma (NHL) patients often experience neurological complications.
- Axonal sensorimotor polyneuropathy is a potential adverse effect of cancer therapy.
Purpose:
- To investigate the incidence and characteristics of axonal sensorimotor polyneuropathy in non-Hodgkin lymphoma patients.
- To determine the correlation between polyneuropathy and specific cancer types or treatments.
Summary:
- A study of non-Hodgkin lymphoma patients revealed axonal sensorimotor polyneuropathy in 15% of cases.
- The polyneuropathy was observed in patients undergoing treatment, particularly those receiving oncovin.
- No correlation was found between polyneuropathy and the specific type of malignancy, suggesting treatment is the primary causative factor.
Impact:
- This research underscores the importance of monitoring for and managing treatment-induced polyneuropathy in non-Hodgkin lymphoma patients.
- Findings emphasize the need for further investigation into oncovin's neurotoxic effects and potential mitigation strategies.